January 29, 1985 - Certificate of Need from the Missouri
Health Facilities Review Committee creating Midwest Stone Institute (MSI) was issued. The
joint venture is a consortium of 13 hospitals and
initially over 50 urologists from the St. Louis area.
October 1985 through March 1986 - Dr. Peter Bub of Germany
serves as the first ESWL/Endourology fellow. Dr. Howard Winfield served
a fellowship under Ralph V. Clayman in Endourology in 1985.
October 24, 1985 - The Dornier HM-3 lithotriptor was installed
and the first kidney stone lithotripsy was performed in Missouri.
October 25, 1985 - The original bylaws that brought Midwest
Stone Institute officially into being were signed.
February 1986 - An outpatient protocol for kidney stone
lithotripsy was established.
July 1986 - Midwest Stone Institute provides physician
training in ESWL as the first AUA certified site in Missouri.
December 1986 - Mallinckrodt Institute of Radiology secures
the right to investigate the second generation lithotriptor known as the Siemens
Lithostar. Performs first treatment. This was the first Lithostar in the
United States.
August 6, 1987 - The Missouri Health Facility Review Committee
approved the agreement between Midwest Stone Institute and Mallinckrodt
Institute of Radiology.
August 31, 1987 - Mallinckrodt Institute of Radiology signs
agreement with Midwest Stone Institute under a Certificate of Need ruling to
enable Mallinckrodt to proceed with their FDA trials under the auspices of
Midwest Stone Institute’s Certificate of Need. Midwest Stone Institute
provides physician support, administrative support, billing & scheduling to
the Lithostar at M.I.R..
June 1988 - Dr. Terri Monk does the first IV sedation
treatment on the HM-3 at MSI. Subsequently, all HM-3 procedures are performed in this
manner.
October 1988 - Siemens Lithostar, after IDE Trials through a
joint effort of Mallinckrodt Radiology and Midwest Stone Institute, received FDA
Approval.
August 1990 - The last month of treatment before Mallinckrodt
Institute of Radiology sold its Siemens Lithostar to a foreign concern.
November 1990 - Midwest Stone Institute successfully adopts the use of the
Jenkins/Gillenwater (University of Virginia) Stryker Frame adaptation for
treatment of mid and lower ureteral stone on the Dornier HM-3.
1991 - Midwest Stone Institute is approved as the first site
in the United States or Canada, for the FDA trials of the EDAP LT-02.
June 3, 1992 - The Missouri Health Facilities Review Committee
CON granted a research exemption to Midwest Stone Institute for studies on the
EDAP LT-02 lithotriptor.
Mid-June 1992 - EDAP LT-02 arrived in the United States.
March 8, 1993 - The first patient was treated on the EDAP
LT-02.
April 1993 - Midwest Stone Institute purchased a mobile
Dornier HM-3.
July 22, 1994 - The first Midwest Stone Institute mobile
lithotripsy was performed.
1997- Midwest Stone Institute partners with academic and community nephrologists to provide patients metabolic stone evaluation services.
1998 - Midwest Stone purchases a mobile LithoTron and Holmium lasers.
August 1998 - Midwest Stone Institute begins participation in
the FDA trial using the OssaTron® shockwave technology for musculoskeletal
conditions.
October 12,2000 - The FDA approves shockwave therapy for the
treatment of chronic proximal plantar fasciitis using the OssaTron®.
March 12, 2002- FDA approves shockwave therapy for
the treatment of tennis elbow or chronic lateral epicondylitis.
2002 - Midwest Stone Institute provides cryosurgery for the
treatment of prostate and kidney cancers as another minimally
invasive surgical procedure.
2003 - Midwest Stone Institute begins brachy-therapy services for the
treatment of prostate cancer.
August 2003 - Midwest Stone Institute begins supporting a Foot and Ankle Fellowship at Washington University School of Medicine, Department of Orthopedics.
January 2006 Midwest Stone Institute begins benign prostatic hyperplasia (BPH) laser ablation services of the prostate. MSI purchases the Storz Modulith SLX F-2 lithotripter.
2007- Initiated providing C-arm services for pain management.
September 2008- Midwest Stone Institute expanded laser services to include KTP greenlight photoselective vaporization of the prostate services.
March 2010- Laser services expanded to treat Nail fungus.
September 2014- Midwest Stone Institute further expanded KTP photoselective laser services for Otolaryngology, and CO2 laser services for Urological, Otolaryngological and Facial Plastic Surgery Services.
To date over 16,000 patients have experienced the miracle of
extracorporeal shockwave lithotripsy (ESWL) and extracorporeal shockwave treatment (ESWT), through the auspices of Midwest Stone Institute. In addition, Midwest Stone
Institute has trained and certified over 400 physicians to provide ESWL therapy
under the permission of the AUA training site committee. Lastly, since 1985,
over 54 fellows in ESWL, Endourology, and ESWT have been supported and trained by
Midwest Stone Institute. Many of these young physicians
have since taken posts in academic centers in the United States,
Germany, Canada, Israel and Austria. |